← Back to Clinical Trials
Recruiting NCT07060742

NCT07060742 Study on the Use of Exergames to Support Older Adults With Psychosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07060742
Status Recruiting
Phase
Sponsor Tobias Melcher
Condition Psychosis
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2025-06-09
Primary Completion 2027-05-15

Eligibility & Interventions

Sex All sexes
Min Age 55 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Dividat SensoOTAGO Falls-prevention program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2025-06-09 with a primary completion date of 2027-05-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to explore a new, engaging approach to support older adults with psychosis-an umbrella term that includes conditions such as schizophrenia, late-onset schizophrenia, and psychotic symptoms resulting from other medical or psychiatric conditions like dementia, delirium, mood disorders, or delusional disorder. As the aging population grows, a rising number of older adults are living with schizophrenia and related disorders, facing not only psychiatric symptoms like hallucinations and delusions but also cognitive impairments, reduced mobility, social isolation, and physical decline. These combined challenges significantly affect daily functioning and quality of life. At present, there are no psychosis treatment guidelines specifically tailored for people aged 60 and above, though general principles from younger populations can be adapted. Evidence suggests that integrating physical and cognitive rehabilitation into standard psychiatric care may enhance treatment outcomes for this age group. One promising method is the use of "exergames"-interactive video games that combine physical movement with cognitive challenges. These games typically require users to perform body movements such as stepping or shifting weight in response to visual and auditory cues, thereby training functions like attention, memory, balance, coordination, and executive function. Exergames offer a playful and stimulating alternative to conventional exercises and are often better accepted by older patients because of their engaging and motivating nature. Previous studies have shown that older adults with schizophrenia not only tolerate these games well but may also experience improvements in mood, cognitive function, and physical activity levels. However, past research has been limited by small sample sizes, lack of control groups, and short intervention periods. This current study, conducted at the Psychiatric University Hospital in Basel, Switzerland, seeks to examine the feasibility and benefits of using an exergame system called Dividat Senso in a more structured and controlled setting. After being screened for eligibility, participants will be randomly assigned to one of two groups. The intervention group will receive usual psychiatric inpatient care, extended with exergame-based motor-cognitive training using the Dividat Senso platform. This device requires full-body interaction, targeting both cognitive functions (such as attention, memory, and executive skills) and physical abilities (such as balance and coordination). The control group will also receive usual care, but instead of exergames, they will participate in traditional strength and balance exercises taken from the Otago falls prevention program. Both groups will train three times a week for four weeks, with each session lasting approximately 20 minutes-totaling 12 sessions. All participants will complete assessments before the intervention begins (T1) and again after four weeks (T2), to measure changes in physical activity, mental well-being, and cognitive performance. By using a structured program and comparing two active interventions, this study aims to generate more robust and generalizable findings on how technology-based, body-and-brain training can support the mental and physical health of older adults with psychosis. If proven feasible and effective, exergame-based rehabilitation could become a valuable and enjoyable addition to psychiatric treatment programs for elderly patients.

Eligibility Criteria

Inclusion Criteria: * Diagnosed psychotic disorders * Able to provide a signed informed consent * Age ≥ 55 years * MoCA ≥ 20 * Physically able to stand for at least 3 minutes without external support (self-report) Exclusion Criteria: * Insufficient knowledge of the German language to understand the instructions, the games, and the assessments * Mobility, cognitive, sensory and/or psychiatric limitations or comorbidities that impair the ability to play the exergames and/or conduct the pre-/post assessments

Contact & Investigator

Central Contact

Tobias Melcher, Dr. Dipl.-Psych.

✉ tobias.melcher@upk.ch

📞 +41 61 325 5163

Principal Investigator

Tobias Melcher, Dr. Dripl.Psych.

STUDY DIRECTOR

Universitäre Psychiatrischen Kliniken (UPK) Basel

Frequently Asked Questions

Who can join the NCT07060742 clinical trial?

This trial is open to participants of all sexes, aged 55 Years or older, studying Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07060742 currently recruiting?

Yes, NCT07060742 is actively recruiting participants. Contact the research team at tobias.melcher@upk.ch for enrollment information.

Where is the NCT07060742 trial being conducted?

This trial is being conducted at Basel, Switzerland.

Who is sponsoring the NCT07060742 clinical trial?

NCT07060742 is sponsored by Tobias Melcher. The principal investigator is Tobias Melcher, Dr. Dripl.Psych. at Universitäre Psychiatrischen Kliniken (UPK) Basel. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology